You are viewing an incomplete version of our website. Please click to reload the website as full version.

Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells

The most commonly used drug in the treatment of women with hormone-dependent breast cancer is tamoxifen. A recent study addressed the issue of tamoxifen leading to a resistance against the drug by investigating the underlying mechanisms, utilizing a GPR30 antibody that is available at antibodies-online.
Continuous treatment of MCF-7 cells (breast cancer cell line) for six months led to resistance against tamoxifen. Similarly, continuous treatment with an agonist for the new estrogen G-protein coupled receptor increases tamoxifen resistance. Hence, this data suggests that receptor signaling is involved in the mediation of tamoxifen induced resistance against this anti-cancer drug. offers a range of .